Biological screening to identify hits the Therapeutic Targets of Alzheimer's disease and their role in the pathogenesis

Alzheimer's disease (AD) is a major problem in today's societies. More than five million Americans are living with Alzheimer's disease in the United States, with the majority being 65 and older. According to the Alzheimer's Association Report, the number of persons affected by Alzheimer's disease in the United States would rise to fourteen million by 2060. The disease, which is the most prevalent form of dementia, is a progressive and irreversible brain disorder that gradually deteriorates an individual's cognitive function. It advances from preclinical to early- to moderate- to late-stage disease. Early symptoms primarily include cognitive impairment, particularly memory loss. Current Alzheimer's disease treatment can be divided into two categories based on the disease's stage. Galantamine, rivastigmine, and donepezil as acetylcholinesterase inhibitors are suitable for mild to moderate cases to provide transient symptomatic relief among patients. Memantine, an N-methyl D-aspartate (NMDA) antagonist, is used as monotherapy to treat symptoms of moderate to severe Alzheimer's disease. These medications are typically selective molecules that target certain proteins (“one compound-one target” method), and their main goal is to restore physiological acetylcholine levels. Nonetheless, multiple pathways of Alzheimer's disease pathogenesis have been hypothesized to far, and they have been proven to overlap and influence one another.